Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Acumen Pharmaceuticals Inc

ABOS ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$2.67

▲ +4.71%

Market Cap $193.09M · Vol 163.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$193.09M

Micro Cap

Div Yield

N/A

EPS Growth

+30.88%

YoY

RSI (14)

77.01

Momentum

Beta

0.39

vs Market

52W High

$3.60

25.83% below

52W Low

$1.21

120.66% above

Volume

163.14K

Avg 108.32K

P/B

1.81

Price-to-book

ROE

-96.20%

Return on equity

Free Float

92.48%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Acumen Pharmaceuticals Inc (ABOS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ABOS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+9.43%

+5.53%

+11.72%

+6.37%

YTD

+26.54%

+90.71%

-62.50%

-82.40%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-121,335,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-96.20%
ROA · ROIC	-67.07% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.81
P/FCF	N/A
EPS Growth	+30.88%
Outstanding Shares	72.32M

Technical Indicators

50-Day SMA	$2.37
200-Day SMA	$2.37
RSI (14)	77.01
Beta	0.39
52-Week High	$3.60
52-Week Low	$1.21

Volume Today	163.14K
Avg Daily Volume (30D)	108.32K
Relative Volume	1.51x
Volatility (10D)	31.85
Volatility (30D)	62.19
Free Float	92.48%

Analyst Consensus

STRONG BUY

Current Price $2.67

Mean Target $7.40

52W Low$1.21 52W High$3.60

Current

Target

$1.21 $3.60

Current Analyst target

+177.15% upside potential · 6 analysts

Identifiers

ExchangeNasdaq

FIGIBBG0058YJ326

ISINUS00509G2093

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.